Abstract 243P
Background
Target sequencing of epithelial ovarian cancer (EOC) has been widely used in clinical to detect the status of BRCA1/2 and genes in homologous recombination repair (HRR) pathway.
Methods
In a prospective study, unselected 215 EOC patients underwent germline and somatic testing with a 25-gene panel, of which 147 patients received target sequencing of 508 genes in OseqT panel. The sensitivity to platinum-based chemotherapy, OS and PFS were explored in various mutation categories.
Results
In 215 patients. 57 (26.51%) patients carried BRCA1 (46, 21.4%) or BRCA2 (14, 6.5%) pathogenic or likely pathogenic variants,3 of them carried both BRCA1 and BRCA2 variants. BRCA1/2 pathogenic carriers had significantly superior PFS and OS than non-mutated group. Deleterious mutation in HRR and MMR related genes can be found in 70 (32.6%) and 3 (1.4%) patients. Among 147 patients using OseqT panel for sequencing, 103 (70.1%), 15 (10.2%), 8 (5.4%), and 15 (10.2%) patients carried mutations of TP53, BRCA1, BRCA2, and PIK3CA mutations. There are also 2, 2 and 3 patients carrying mutations of p.E542K, p.E545K and p.H1047R mutations in PIK3CA , respectively. Mutations in ARID1A (11 patients, 7.4%), NF1 (7, 4.7%) and PTEN (6, 4.1%) can also be detected. In 118 patients received MSI testing, 22 (18.6%) of them are microsatellite instability (MSI)-low.
Conclusions
While BRCA1/2 and HRR related gene is still the most important target for gene test of EOC patient. The high prevalence of other cancer related gene such as PIK3CA cannot be overlooked. Large panel containing more cancer related genes may provide extra suggestions for doctors.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session
134P - Effect of preoperative tumour under-staging on the long-term survival of patients undergoing radical gastrectomy for gastric cancer
Presenter: Mi Lin
Session: e-Poster Display Session
135P - Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Presenter: Hirohito Fujikawa
Session: e-Poster Display Session
136P - Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
Presenter: Wen-Wu Qiu
Session: e-Poster Display Session
137P - Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)
Presenter: Mikhail Fedyanin
Session: e-Poster Display Session
138P - Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer
Presenter: Ying-Qi Huang
Session: e-Poster Display Session
139P - An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer
Presenter: Zhi-Yu Liu
Session: e-Poster Display Session
140P - Preoperative and postoperative C-reactive protein levels predict recurrence and chemotherapy benefit in gastric cancer
Presenter: Li-Li Shen
Session: e-Poster Display Session
141P - Low expression of CDK5RAP3 and UFM1 indicates poor prognosis in patients with gastric cancer
Presenter: Ning-Zi Lian
Session: e-Poster Display Session
142P - Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopy and open radical gastrectomy for gastric cancer: A propensity score-matching analysis
Presenter: Si-Jin Que
Session: e-Poster Display Session